Pearls & Oy-sters: Leber Hereditary Optic Neuropathy-Plus Masquerading as Neuromyelitis Optica Spectrum Disorder in a 2-Year-Old Child

Author(s):
Alex Sunshine1,1; Quinton J Mandle1; Ana M Cabal Herrera, MD1; Bianca Zapanta3; Hersh Varma4; Setty Magaña1

Corresponding Author:
Setty Magaña, Setty.Magana@nationwidechildrens.org

Affiliation Information for All Authors: 1. Neurology, Nationwide Children's Hospital; 2. Pediatrics, Nationwide Children's Hospital; 3. Genetics, Nationwide Children's Hospital; 4. Ophthalmology, Nationwide Children's Hospital

Equal Author Contribution:
Alex Sunshine and Quinton Mandle contributed equally as co-first authors

Contributions:
Alex Sunshine: Drafting/revision of the manuscript for content, including medical writing for content
Quinton J Mandle: Drafting/revision of the manuscript for content, including medical writing for content
Ana Maria Cabal Herrera: Drafting/revision of the manuscript for content, including medical writing for content
Bianca Zapanta: Major role in the acquisition of data
Hersh Varma: Major role in the acquisition of data
Setty Magaña: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data; Study concept or design; Analysis or interpretation of data
Acknowledgment:
We thank care providers in the Nationwide Children’s Hospital multidisciplinary neuroimmunology clinic, including Dr. Alana Leaver, PsyD, who provided direct patient care, as well as Paolo Loreto Palacio, who participated in research enrollment.

Study Funding:
Research reported in this publication was supported by the National Institute of Neurological Disorders and Stroke of the National Institutes of Health under award number K12NS098482 (SMM)

Disclosure:
The authors report no relevant disclosures.

Preprint DOI:

Received Date:
2023-05-19

Accepted Date:
2023-09-27

Handling Editor Statement:
Submitted and externally peer reviewed. The handling editor was Resident & Fellow Section Deputy Editor Ariel Lyons-Warren, MD, PhD.
Abbreviations (in alphabetical order): AQP4 - aquaporin-4; CT - computed tomography; LHON - Leber hereditary optic neuropathy; MAGEL-2 - MAGE Family Member L2; MOG - myelin oligodendrocyte glycoprotein; MOGAD - myelin oligodendrocyte glycoprotein antibody-associated diseases; MS - Multiple sclerosis; NMOSD – neuromyelitis optica spectrum disorder; OCB - oligoclonal bands

Pearls:
- “LHON-Plus” is a phenotype of LHON that is characterized by extraocular neurologic manifestations which may be the first manifestations of the disease.
- Extraocular manifestations of LHON-Plus can include movement disorders, peripheral neuropathy, seizures, and demyelinating-like syndromes

Oy-sters:
- LHON-Plus can be highly difficult to distinguish from acquired demyelinating diseases based on radiologic findings alone, although a predilection for the dorsal columns in the spinal cord has been noted in LHON-Plus
- In rare cases, the co-occurrence of AQP4+ NMOSD and LHON has been reported

Case report:
A 2-year-old, generally healthy Caucasian female with one month of hyperphagia associated with weight gain from the 90th percentile to the 98th percentile for age, along with fatigue, incoordination, and hiccups presented to the emergency department with a transient episode of unresponsiveness. Review of systems was negative for recent febrile illnesses, diarrhea, rashes, or travel. Family history was notable for a strong maternal history of LHON (Figure 1). Exam displayed encephalopathy and hypoxemia to 70% SpO2; chemistry panel was pertinent for hyponatremia to 123 mmol/L. Complete blood count, urinalysis, and urine drug screen were unremarkable. Computed tomography (CT) of the head was normal. While in the emergency department she had a second witnessed episode of unresponsiveness concerning for seizure, resulting in intubation and admission to the intensive care unit (ICU).
The patient’s ICU course was complicated by ongoing respiratory failure and neurogenic bowel and bladder. She was noted to have ataxic respirations, cerebral salt wasting, and dysautonomia causing fevers and hypertension. Extended electroencephalogram monitoring showed diffuse slowing but no epileptiform discharges. Extensive initial work-up, including sepsis evaluation, routine cerebrospinal fluid (CSF) studies, CSF metabolites, rheumatologic labs, CSF meningitis-encephalitis panel, CSF herpes simplex virus, enterovirus polymerase chain reaction, metabolic screening labs, and endocrinologic testing of the thyroid, glucocorticoid, and gonadotropin axes was unrevealing. Magnetic resonance imaging (MRI) of the brain and spine revealed T2-hyperintense lesions of the right substantia nigra, bilateral inferior colliculi, dorsal medulla, and most of the cervical and thoracic spinal cord, favored to represent demyelination (Figure 2). CT with contrast of the chest, abdomen and pelvis was normal. She was then transferred to another hospital for ongoing care.

Further workup was initiated after hospital transfer. CSF oligoclonal bands (OCB), serum anti-myelin oligodendrocyte (MOG), and anti-aquaporin 4 (AQP4) antibodies by cell-based assay were negative. Dilated fundoscopic exam by ophthalmology was documented as normal and without disc pallor. She was found to have positive low-titer anti-N-methyl D-aspartate receptor (NMDAR) serum antibodies at 1:10; however, CSF anti-NMDAR titers were negative. Given her recent history of hyperphagia and weight gain, Prader-Willi methylation studies, congenital hypoventilation, and obesity panels were sent, disclosing a variant of uncertain significance in the MAGEL2 gene concerning for Schaaf-Yang syndrome. Her case was discussed with several neuroimmunologists at various institutions. The temporal course of acute neurological symptoms, combined with brain and spinal cord lesions were suggestive of an acquired central nervous system demyelinating disease, including neuromyelitis optica spectrum disorder (NMOSD), acute disseminated encephalomyelitis (ADEM), or myelin oligodendrocyte glycoprotein associated disorder (MOGAD). Due to the constellation of diencephalic and area postrema syndromes, longitudinally-extensive transverse myelitis, and negative anti-AQP4 and anti-MOG
antibodies, she was given a provisional diagnosis of antibody-negative NMOSD. Her treatment course consisted of daily intravenous methylprednisolone 30 mg/kg for five days, ten exchanges of plasmapheresis, rituximab 375 mg/m², and a thirty-day prednisolone taper. Repeat MRI of the brain two weeks later demonstrated improvement of the aforementioned T2 hyperintense lesions, as well as new T2 hyperintense lesions of bilateral cranial nerves VII and VIII. Auditory brainstem response testing was normal. She was gradually weaned off respiratory support on ICU day nineteen, and was transferred to the floor. Her mental status gradually improved, and she was eventually discharged with neuroimmunology follow-up.

After discharge the patient’s symptoms continued to resolve, noting only residual fatigue and incoordination. Given the patient’s family history of LHON, she was referred to genetics and ophthalmology, but due to the patient’s mother’s own poor vision attributable to LHON, transportation barriers did not allow family to make these appointments. Repeat MRI of the brain and spine demonstrated further improvement of the previously noted right substantia nigra, brainstem, and spinal cord lesions. Repeat anti-MOG and anti-AQP4 antibodies were negative. After extensive multi-institutional discussions, the variant of uncertain significance in the MAGE2 gene was thought to be benign, and her low serum NMDA antibody titer was considered incidental. She continued to undergo scheduled rituximab infusions with no recurrence of symptoms. After two years the patient was able to undergo genetic mitochondrial testing, which revealed a pathogenic point mutation in m.14484T>C (MT-ND6,p.Met64Val). Repeat dilated ophthalmologic exam now revealed mild decreased visual acuity bilaterally and optic nerve pallor. Retinal nerve fiber layer testing showed severe bilateral thinning. Given her strong family history of LHON, bilateral optic nerve atrophy, and persistently negative anti-AQP4 antibodies, her diagnosis was revised to LHON-Plus. After shared decision-making with the patient’s family, rituximab treatment was discontinued with a plan to serially monitor anti-AQP4 antibodies for potential seroconversion.
**Discussion:** LHON is the most common mitochondrial disease. It characteristically causes sequential optic neuropathy, most commonly in young adults, which progresses over weeks to months and leads to blindness\(^1\). A minority of cases have childhood-onset, and it has been suggested that these patients may have slower progression of vision loss compared to teenagers and adults\(^2\). Several genetic variants in mitochondrial genes encoding proteins in complex I of the electron transport chain have been implicated in the disease, with the most common being point mutations including m.3460G>A (MT-ND1, p.Ala52Thr), m.11778G>A (MT-ND4, p.Arg340His), m.14484T>C (MT-ND6,p.Met64Val), and m.3460G>A (MT-ND1, p.Ala52Thr). The disease is inherited in a matrilineal fashion but displays incomplete penetrance due to heteroplasmy and has a male predominance\(^3,4\). No FDA-approved therapy exists currently, although the coenzyme-Q10 analog Idebenone is approved for treatment of LHON in Europe, and gene therapy with adenovirus vectors is in development\(^5,6\).

“LHON-Plus” is a designation given to patients with LHON who display extraocular manifestations attributable to the disease. Neurologic manifestations in LHON-Plus include seizures, movements disorders, paraplegia, encephalopathy, peripheral neuropathy, and myopathy. In a case series of patients with LHON (n=46), 59% (n=27) had neurologic signs or extraocular symptoms\(^7\). These protean manifestations are perhaps unsurprising given the ubiquity of the electron transport chain, and likely reflect preferential involvement of metabolically active organs, such as the brain and muscle. Interestingly, there are reports of LHON-Plus with brain and spinal cord matter lesions mimicking acquired demyelinating diseases, such as MS, NMOSD and MOGAD\(^8,9\). Such presentations can be highly difficult to distinguish from acquired demyelinating diseases based on radiologic findings alone, although a predilection for the dorsal columns in the spinal cord has been noted in LHON-Plus\(^10\). In these patients, the diagnosis of LHON-Plus was made after pathogenic mutations consistent with LHON-Plus were revealed and disease markers such as CSF OCB or serum anti-AQ4 and anti-MOG antibodies were negative.
While there are multiple pediatric case reports of LHON-Plus, to our knowledge our patient is the youngest to present with neurologic symptoms consistent with the disease.\textsuperscript{11, 12} Our patient’s presentation was dominated by severe encephalopathy with an associated medullary lesion, which, combined with the patient’s very young age and inability to participate with the visual exam, likely obfuscated the trademark vision loss of LHON. However, her monophasic course, presumed lack of ocular pain traditionally associated with optic neuritis, and family history of LHON were clues to her diagnosis. Although LHON and NMO are both quite rare, there have been case reports of patients with both pathogenic mtDNA mutations for LHON and AQP4+ NMO\textsuperscript{11,13}. It has been hypothesized that mtDNA mutations might be associated with AQP4 autoimmunity and predispose to NMO, however this remains to be clarified\textsuperscript{13}. In our patient, anti-AQP4 antibodies will continue to be monitored for potential seroconversion.

This case illustrates several important points. First, while LHON is traditionally associated with optic neuropathy, it can also cause a myriad of neurologic symptoms involving the central and peripheral nervous systems. Young patients who will eventually be diagnosed with LHON-Plus may be too young to endorse visual symptoms or cooperate with formal visual acuity testing, and as a result will first present with other neurologic signs or symptoms. Secondly, LHON-Plus can mimic acquired demyelinating diseases, such as MS, NMOSD and MOGAD, and should be kept in the differential for patients with progressive vision loss, especially if accompanied by demyelinating-like lesions in the brain and spinal cord. In such cases, a retrospective clue to a diagnosis of LHON-Plus may be the lack of recurrent attacks often seen in multiphasic acquired demyelinating diseases. Moreover, the rarity of each entity, NMOSD and LHON, does not preclude the co-occurrence of both entities, as has been described in rare adult cases\textsuperscript{12}. Finally, it is important to emphasize that LHON is a genetic diagnosis; accordingly, a diagnosis of LHON-Plus is contingent upon appropriate genetic testing and ruling out possible concomitant neurologic illnesses.
Figure 1. Genetic pedigree with age in years and designation of individuals with LHON. The patient is marked with a black arrow.
**Figure 2. Brain and spine imaging.** MRI of the brain showing T2 fluid attenuated inversion recovery signal abnormality in the bilateral dorsal medulla in the axial (A), coronal (B) and sagittal (C) planes. Sagittal MRI of the spinal cord demonstrating a longitudinally extensive T2 hyperintense signal abnormality in the cervical spinal cord (D).
References:


Pearls & Oyster: Leber Hereditary Optic Neuropathy-Plus Masquerading as Neuromyelitis Optica Spectrum Disorder in a 2-Year-Old Child
Alex Sunshine, Quinton J Mandle, Ana M Cabal Herrera, et al.

Neurology published online October 12, 2023
DOI 10.1212/WNL.00000000000207979

This information is current as of October 12, 2023

Updated Information & Services
including high resolution figures, can be found at:
http://n.neurology.org/content/early/2023/10/12/WNL.00000000000207979.citation.full

Subspecialty Collections
This article, along with others on similar topics, appears in the following collection(s):
Devic's syndrome
http://n.neurology.org/cgi/collection/devic_syndrome
Mitochondrial disorders
http://n.neurology.org/cgi/collection/mitochondrial_disorders

Permissions & Licensing
Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:
http://www.neurology.org/about/about_the_journal#permissions

Reprints
Information about ordering reprints can be found online:
http://n.neurology.org/subscribers/advertise